The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Applying genomic analysis to refine unclassified renal cell carcinoma.
 
Emre Yekeduz
No Relationships to Disclose
 
David A. Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Dedham Group; Defined Health; DLA Piper; Eisai; Elephas Bio; Exelixis; Insight Strategy; Link Cell Therapies; Merck; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
Chris Labaki
No Relationships to Disclose
 
Marc Machaalani
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Rashad Nawfal
No Relationships to Disclose
 
Eddy Saad
No Relationships to Disclose
 
Renee Maria Saliby
No Relationships to Disclose
 
Karl Semaan
No Relationships to Disclose
 
Maxine Sun
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
 
Michelle S. Hirsch
No Relationships to Disclose
 
Yüksel Ürün
Honoraria - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Gilead Sciences; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Gilead Sciences; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - Abdi Ibrahim; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Abdi Ibrahim; Bristol-Myers Squibb; Eczacibasi; Gen Ilaç; Pfizer; Roche
 
Talal El Zarif
No Relationships to Disclose
 
Toni K. CHOUEIRI
Stock and Other Ownership Interests - Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel